Madrigal Pharmaceuticals Inc. (MDGL) announced Wednesday morning that its Phase 2 trial of MGL-3196, in patients with biopsy-proven non-alcoholic steatohepatitis, met its primary endpoint.
from RTT - Before the Bell http://ift.tt/2AZULuL
via IFTTT
No comments:
Post a Comment